A timely oral option: single-agent vinorelbine in Desmoid tumors

Show simplified metadata
dc.contributor.authorGennatas, Spyridon
dc.contributor.authorChamberlain, Florence
dc.contributor.authorSmrke, Alannah
dc.contributor.authorStewart, James
dc.contributor.authorHayes, Andrew
dc.contributor.authorRoden, Lorna
dc.contributor.authorMessiou, Christina
dc.contributor.authorKowa, Jie-Ying
dc.contributor.authorEstival, Anna
dc.contributor.authorChauhan, Dharmisha
dc.contributor.authorThway, Khin
dc.contributor.authorFisher, Cyril
dc.contributor.authorvan der Graaf, Winette T A
dc.contributor.authorJones, Robin L
dc.contributor.authorBenson, Charlotte
dc.contributor.departmentCellular pathologyen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.trustauthorFisher, Cyril
dc.date.accessioned2025-04-09T13:06:03Z
dc.date.available2025-04-09T13:06:03Z
dc.date.issued2020-10-02
dc.description.abstractIntroduction: Desmoid tumors (DT) are rare collagen-forming tumors that can exhibit locally aggressive patterns of behavior. The aim of this study was to evaluate the efficacy and safety of treatment of DT with single-agent oral vinorelbine. Materials and methods: A retrospective review of patients treated with vinorelbine 90 mg orally on days 1, 8, and 15 of a 28-day cycle from January 2004 to July 2019 was performed. Response was assessed using RECIST version 1.1. Descriptive statistics were employed. Results: A total of 29 patients were included. Response rate was 20.7% (6/29), and clinical benefit rate (response by RECIST 1.1 and/or clinical symptom improvement) was 65.5% (19/29). No patient experienced grade 3 or above toxicity. Common toxicities were grade 1-2 nausea (14/26, 48.3%), fatigue (9/26, 31.0%), and diarrhea (4/26, 13.8%). Conclusion: Single-agent oral vinorelbine is an effective, safe, and well-tolerated treatment for DT. It represents a new oral alternative for management of DT.en_US
dc.identifier.citationGennatas S, Chamberlain F, Smrke A, Stewart J, Hayes A, Roden L, Messiou C, Kowa JY, Estival A, Chauhan D, Thway K, Fisher C, van der Graaf WTA, Jones RL, Benson C. A Timely Oral Option: Single-Agent Vinorelbine in Desmoid Tumors. Oncologist. 2020 Dec;25(12):e2013-e2016. doi: 10.1002/ONCO.13516. Epub 2020 Oct 2en_US
dc.identifier.doi10.1002/ONCO.13516
dc.identifier.eissn1549-490X
dc.identifier.issn1083-7159
dc.identifier.pmid32918789
dc.identifier.urihttp://hdl.handle.net/20.500.14200/7396
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.urlhttp://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1549-490Xen_US
dc.rights© 2020 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
dc.source.beginpagee2013
dc.source.countryEngland
dc.source.endpagee2016
dc.source.issue12
dc.source.journaltitleThe Oncologisten_US
dc.source.volume25
dc.subjectOncologyen_US
dc.titleA timely oral option: single-agent vinorelbine in Desmoid tumorsen_US
dc.typeArticleen_US
dc.typeOtheren_US
dspace.entity.typePublication
oa.grant.openaccessnaen_US
rioxxterms.versionNAen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.7 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Oncology